CD69 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results revealed that NKT-like cells are decreased in treated CML patients, although they present increased expression of activation markers (CD69 and HLA-DR), increased degranulation (CD107a) and impaired IFN-γ production.